NCT06066437 2026-03-05
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
21 trialsNCT05546268 2026-03-03
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT02522715 2026-02-24
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Active not recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT04946370 2026-02-03
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT03543189 2026-01-29
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT05968144 2026-01-27
ADRIAN
University of Maryland, Baltimore
Phase 1/2 Active not recruiting
NCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05540392 2025-10-10
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT05011188 2025-08-27
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1/2 Active not recruiting
NCT01688492 2025-08-12
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04194554 2025-06-04
ASCLEPIuS
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT03689699 2025-04-29
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Columbia University
Phase 1/2 Active not recruiting
NCT04619069 2025-04-17
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
Sunnybrook Health Sciences Centre
Phase 1/2 Active not recruiting
NCT05067140 2025-03-17
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis
Phase 1/2 Active not recruiting
NCT05383079 2025-02-07
AlphaBet
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT05547061 2024-12-11
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Cellbion Co., Ltd.
Phase 1/2 Active not recruiting
NCT04430192 2024-11-08
LuTectomy
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT03444844 2022-05-02
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Five Eleven Pharma, Inc.
Phase 1/2 Active not recruiting